# Signals Article: Putative Target Q9NNX6 for Lassa Fever Therapeutic Development
Background
Lassa fever, caused by the Lassa virus (LASV), is an acute viral hemorrhagic illness endemic to West Africa. The disease is transmitted primarily through contact with the urine or feces of infected rodents, and it can lead to severe complications, including multi-organ failure and death. Despite its significant public health impact, effective therapeutics for Lassa fever remain limited. A putative target candidate, Q9NNX6, has been identified through recent data-mining efforts, suggesting its potential role in the pathogenesis of Lassa fever and warranting further investigation.Data-mining rationale
The identification of Q9NNX6 as a putative target was derived from a comprehensive analysis of UniProt's reviewed human entries for "Lassa fever," cross-referenced against nine microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate Q9NNX6 was found to appear in several expression-profiling studies; however, it lacks any registered Phase 1 or higher clinical program. This absence indicates an opportunity for further exploration of its therapeutic potential. Additionally, many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, suggesting that a re-analysis could yield more robust insights.Why prior analyses may have missed this
Prior analyses may have overlooked the significance of Q9NNX6 due to several factors. The datasets analyzed were generated using older statistical methodologies that may not have adequately controlled for multiple testing, potentially obscuring the identification of differentially expressed genes. Furthermore, the complex interactions between LASV and host immune responses may have diluted the signal for specific targets in earlier studies. The absence of a clinical program for Q9NNX6 further suggests that its therapeutic potential has not been fully explored in the context of Lassa fever infection.Reasoning for further validation
To validate the potential of Q9NNX6 as a therapeutic target for Lassa fever, the following experimental approaches are recommended: 1. **Re-analyze GEO Datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to re-analyze the matched GEO datasets, which may reveal more accurate differential expression results. 2. **Validate Differentially-Expressed Genes**: Conduct quantitative PCR (qPCR) validation of the top differentially expressed genes identified in the re-analysis using an independent cohort to confirm their relevance in Lassa fever. 3. **Check Tissue Specificity**: Investigate the tissue specificity of Q9NNX6 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its potential as a therapeutic target. 4. **Pathway Context Analysis**: Employ STRING or OmniPath databases to explore the biological pathways associated with Q9NNX6, providing context for its role in Lassa virus pathogenesis. 5. **Assess Druggability**: If Q9NNX6 is validated as a relevant target, evaluate its druggability using databases such as DGIdb and ChEMBL to identify potential small molecules or compounds that could be developed into therapeutics.References
- UniProt: Q9NNX6
- UniProt: Q14118
- GEO Datasets: GDS:200294797, GDS:200290786, GDS:200041300, GDS:5058, GDS:200033687